

Part I: Description of consignment	I.1. Consignor Name Address Country ISO Code		I.2. IMSOC reference	I.2.a. Local reference	
				I.3. Central Competent Authority	
				I.4. Local Competent Authority	
	I.5. Consignee Name Address Country ISO Code		I.6. Operator conducting assembly operations independently of an establishment Name Address Approval Number Country ISO Code		
	I.7. Country of origin ISO Code		I.9. Country of destination ISO Code		
	I.8. Region of origin Code		I.10. Region of destination Code		
	I.11. Place of dispatch Name Address Approval Number Country ISO Code		I.12. Place of destination Name Address Approval Number Country ISO Code		
	I.13. Place of loading Name Address Approval Number Country ISO Code		I.14. Date and time of departure		
	I.15. Means of Transport		I.16. Transporter		
	Mode	International transport document	Identification	Name Address Approval Number Country ISO Code	
			I.17. Accompanying documents		
			[en] accompanying document number	Date of issue	
			Country	Place of issue	
I.18. Transport conditions Chilled <input type="checkbox"/> Frozen <input type="checkbox"/> Ambient <input type="checkbox"/>					
I.19. Container No / Seal No					
I.20. Certified as Germinal products <input type="checkbox"/>					
I.21. For transit through a third country <input type="checkbox"/>					
Third country		ISO Code			
Exit point		BCP code			
Entry point		BCP code			
I.22. For transit through Member State(s) <input type="checkbox"/>		I.23. For export <input type="checkbox"/>			
Member State ISO Code		Third country ISO Code			
		Exit point BCP code			
I.24. Estimated journey time		I.25. Journey Log			
I.26. Total number of packages		I.27. Total quantity			
I.28. Total gross weight					
I.30. Description of consignment					
Commodity	Species	Identification Number	Quantity	Nature of commodity	
Identification Mark	Package count	Date of collection / production	Plant / Establishment / Centre		

Part II: Certification	II. Health information		
	<p>I, the undersigned official veterinarian, hereby certify that:</p> <p>(1) <input type="checkbox"/> II.1. The in vivo derived embryos of equine animals described in Part I have been collected, processed and stored, and dispatched by the embryo collection team(2) which</p> <p>II.1.1. is approved and kept in a register by the competent authority;</p> <p>II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]</p> <p>(1) <input type="checkbox"/> II.1. The oocytes(1)/ in vitro produced embryos(1)/ micromanipulated embryos(1) of equine animals described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team(2) which</p> <p>II.1.1. is approved and kept in a register by the competent authority;</p> <p>II.1.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]</p> <p>II.2. The oocytes(1)/ embryos(1) described in Part I are intended for artificial reproduction and were obtained from donor animals which</p> <p>II.2.1. have been born and remained since birth in the Union, or have entered the Union in accordance with the requirements for entry into the Union;</p> <p>II.2.2. come from establishments in a Member State or zone thereof, or from establishments under official control by the competent authority in a third country or territory, or a zone thereof</p> <p>II.2.2.1. in which surra (<i>Trypanosoma evansi</i>) has not been reported during the period of the preceding 30 days prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and</p> <p>(1) <input type="checkbox"/> either [surra has not been reported in the establishment during the period of the preceding 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]</p> <p>(1) <input type="checkbox"/> or [surra has been reported in the establishment during the period of the preceding 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak the establishment has remained under movement restrictions</p> <p>(1) <input type="checkbox"/> either [until the remaining animals in the establishment have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the last infected animal has been removed from the establishment;]]</p> <p>(1) <input type="checkbox"/> or [for at least 30 days from the date of cleaning and disinfection after the last animal of listed species on the establishment was either killed and destroyed or slaughtered;]]</p> <p>II.2.2.2. in which dourine has not been reported during the period of the preceding 6 months prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and</p> <p>(1) <input type="checkbox"/> either [dourine has not been reported in the establishment during the period of the preceding 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]</p> <p>(1) <input type="checkbox"/> or [dourine has been reported in the establishment during the period of the preceding 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak, the establishment has remained under movement restrictions</p>		

Part II: Certification	II. Health information			
	(1)	○ either	[until the remaining equine animals in the establishment, except castrated male equine animals have been subjected to a test for dourine with the diagnostic method provided for in Part 8 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the infected animals have been killed and destroyed or slaughtered, or the infected entire male equine animals have been castrated;]	
	(1)	○ or	[for at least 30 days after the last equine animal on the establishment was either killed and destroyed or slaughtered, and the premises were cleaned and disinfected;]	
	II.2.2.3.		in which equine infectious anaemia has not been reported during the period of the preceding 90 days prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and	
	(1)	○ either	[equine infectious anaemia has not been reported on the establishment during the period of the preceding 12 months prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]	
	(1)	○ or	[equine infectious anaemia has been reported on the establishment during the period of the preceding 12 months prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak the establishment has remained under movement restrictions	
	(1)	○ either	[until the remaining equine animals in the establishment have been subjected to a test for equine infectious anaemia with the diagnostic method provided for in Part 9 of Annex I to Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken on two occasions with a minimum interval of 3 months after the infected animals have been killed and destroyed or slaughtered and the establishment was cleaned and disinfected;]	
	(1)	○ or	[for at least 30 days after the last equine animal on the establishment was either killed and destroyed or slaughtered, and the premises were cleaned and disinfected;]	
	II.2.3.		were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the day of collection of the oocytes(1)/ embryos(1);	
	II.2.4.		are identified as provided for in Article 58(1), 59(1) or 62(1) of Commission Delegated Regulation (EU) 2019/2035;	
	II.2.5.		for a period of at least 30 days prior to the date of first collection of the oocytes(1)/ embryos(1) and during the collection period	
	II.2.5.1.		were kept on establishments not situated in a restricted zone established due to the occurrence of African horse sickness, infection with <i>Burkholderia mallei</i> (glanders) or of an emerging disease relevant for equine animals;	
	II.2.5.2.		were kept on a single establishment where Venezuelan equine encephalomyelitis, dourine, surra (<i>Trypanosoma evansi</i>), equine infectious anaemia, contagious equine metritis (<i>Taylorella equigenitalis</i>), infection with rabies virus and anthrax have not been reported;	
	II.2.5.3.		were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.2.5.1. or from establishments which do not meet the conditions referred to in point II.2.5.2.;	
II.2.6.		were not used for natural breeding during a period of at least 30 days prior to the date of the collection of the oocytes(1)/ embryos(1) and between the date of the first samples referred to in points II.2.7.1. and II.2.7.2. and the date of the collection of the oocytes(1)/ embryos(1);		
II.2.7.		have been subjected to the following tests, referred to in points 2(b) and (c) of Chapter II of Part 4 of Annex II to Delegated Regulation (EU) 2020/686, as follows:		

II. Health information			
	II.2.7.1.	for equine infectious anaemia (EIA), an agar-gel immuno-diffusion test (AGID or Coggins test) or an enzyme-linked immunosorbent assay (ELISA) with a negative result carried out on a blood sample taken on _____.(3), being not less than 14 days following the date of commencement of the period referred to in point II.2.6, and the test was last carried out on a blood sample taken on _____.(3), being not more than 90 days prior to the date of the collection of the oocytes(1)/embryos(1) intended for movement to another Member State;]	
	II.2.7.2.	for contagious equine metritis (CEM), an agent identification test carried out with a negative result on at least two specimens (swabs) taken during the period referred to in point II.2.6. from at least the mucosal surfaces of the clitoral fossa and the clitoral sinuses of the donor mare	
(1)	<input type="checkbox"/> either	[II.2.7.2.1. on two occasions with an interval of not less than 7 days on _____ (3) and on _____ (3), in the case of isolation of <i>Taylorella equigenitalis</i> after cultivation under microaerophilic conditions for a period of at least 7 days, set up within 24 hours after taking the specimens from the donor animal, or 48 hours where the specimens are kept cool during transport.]	
(1)	<input type="checkbox"/> and/or	[II.2.7.2.2. on one occasion on _____ (3), in the case of detection of genome of <i>Taylorella equigenitalis</i> by a polymerase chain reaction (PCR) or real-time PCR, carried out within 48 hours after taking the specimens from the donor animal.]	
The samples referred to in points II.2.7.2.1. and II.2.7.2.2. were in no case taken earlier than 7 days (systemic treatment) or 21 days (local treatment) after antimicrobial treatment of the donor mare and were placed in transport medium with activated charcoal, such as Amies medium, before dispatch to the laboratory.			
II.3.	The oocytes(1)/ embryos(1) described in Part I		
	II.3.1.	has been collected, processed and stored in accordance with animal health requirements set out in Part 2(1)/Part 3(1)/Part 4(1)/Part 5(1) and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;	
	II.3.2.	are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 10 of Delegated Regulation (EU) 2020/686 and that mark is indicated in Box I.30;	
	II.3.3.	are transported in a container which:	
	II.3.3.1.	was sealed and numbered prior to the dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in Box I.19;	
	II.3.3.2.	has been cleaned and either disinfected or sterilised before use, or is single-use container;	
(1)(4)	<input type="checkbox"/>	[II.3.3.3. has been filled in with the cryogenic agent which not have been previously used for other products;]	
(1)(5)	<input type="checkbox"/>	[II.3.4. are placed in straws or other packages which are securely and hermetically sealed;	
	II.3.5.	are transported in a container where they are separated from each other by physical compartments or by being placed in secondary protective bags.]	
(1)(6)	<input type="checkbox"/>	The in vivo derived embryos(1)/ in vitro produced embryos(1)/ micromanipulated embryos(1) described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a Member State or by the competent authority of a third country, territory or zone thereof listed in Annex XII to Commission Implementing Regulation (EU) 2021/404.]	
(1)(7)	<input type="checkbox"/>	The following antibiotic or mixture of antibiotics(7) has been added to the collection, processing, washing or storage media: _____.]	
II.5.			

Part II: Certification	II. Health information	
	<p>Notes</p> <p>This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.</p>	
Part I:		
Box reference	“Place of dispatch”: Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.	
I.11:		
Box reference	“Place of destination”: Indicate the address and unique registration or approval number of the establishment of destination of the consignment of oocytes or embryos.	
I.12:		
Box reference	Seal number shall be indicated.	
I.19:		
Box reference	Total number of packages shall correspond to the number of containers.	
I.26:		
Box reference	“Type”: Specify if in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos.	
I.30:		
“Identification number”: Indicate identification number of each donor animal.		
“Identification mark”: Indicate mark on the straw or other packages where oocytes or embryos of the consignment are placed.		
“Date of collection/production”: indicate the date on which oocytes or embryos of the consignment was collected or produced.		
“Approval or registration number of plant/establishment/centre”: Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos were collected or produced.		
“Quantity”: Indicate number of straws or other packages with the same mark.		
Part II:		
(1)	Delete if not applicable.	
(2)	Only embryo collection or production teams approved by the competent authority and included in the register referred to in Article 101(1)(b) of Regulation (EU) 2016/429 and Article 7 of Delegated Regulation (EU) 2020/686.	
(3)	Insert date in the following format: dd.mm.yyyy.	
(4)	Applicable for frozen oocytes or embryos.	
(5)	Applicable for the consignment where in one container oocytes, in vivo derived embryos, in vitro produced embryos and micromanipulated embryos of equine animals are placed and transported.	
(6)	Does not apply to oocytes.	
(7)	Mandatory attestation in case antibiotics were added.	
(8)	Insert the name(s) of the antibiotic(s) added and its(their) concentration.	
Certifying Officer/Official veterinarian		
Name (in capital letters)	Qualification and title	
Date of signature	Signature	
Stamp		